Course Summary
Contact Hour(s):
2 Contact Hours
Contact hours for LPNs in any state are earned by completing this course. This is part of a series of 24 contact hours of courses to prepare for LPN IV Certification in Florida. Florida certification participants must schedule a 6-hour live presentation and return demonstration to complete IV Certification. The live presentation is not provided by CEUFast.com.
Author:
Desiree Reinken, PhD, APRN, NP-C
Julia Tortorice, RN, MBA, MSN, EdD, NEA-BC
This peer-reviewed course is applicable for the following professions:
Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Nursing Student, Registered Nurse (RN)
Accreditations:
The American Nurses Credentialing Center (ANCC)
State Approvals:
Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353
Course Description:
This course discusses the rights of medication administration, including the foundational rights of “right patient,” “right route,” “right time,” “right medication,” and “right dose.” It also discusses considerations for medication administration of special populations, such as the very young, the elderly, and pregnant women. Also discussed in this course are specific methods of IV administration, such as IV push, and recommended best practices.
Outcomes
≥ 92% of participants will know the rights of medication administration.
Objectives
After completing the course, the learner will be able to:
- Summarize the rights that serve as the standard for legal accountability in medication administration.
- Identify the types of patients who require special consideration when administering medications.
- Outline the best practices recommended by the Institute of Safe Medication Practices in IV administration.
- Compare various IV administration methods.
- Evaluate medication and fluid compatibility.
Disclosures:
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
